滄州明珠(002108.SZ):擬以4363.59萬元收購隔膜科技餘下3.0147%股權
格隆匯6月20日丨滄州明珠(002108.SZ)公佈,公司於2023年6月20日召開第八屆董事會第十二次(臨時)會議、第八屆監事會第八次(臨時)會議,審議通過了《關於收購控股子公司少數股權暨關聯交易的議案》,並於同日在滄州同相關股東簽訂《股權轉讓協議書》,公司以自有貨幣資金4363.59萬元收購少數股東持有的控股子公司滄州明珠隔膜科技有限公司(簡稱“隔膜科技”)的1889萬元出資額,佔隔膜科技註冊資本的比例為3.0147%。本次交易完成後,公司持有隔膜科技的股權將由96.9853%增加至100%,隔膜科技成為公司全資子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.